Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;16(1):116-23.
doi: 10.4103/2230-8210.91206.

Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome

M K Garg  1 , M K Dutta, Namita Mahalle
Affiliations

Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome

M K Garg et al. Indian J Endocrinol Metab. 2012 Jan.

Abstract

Background: The clustering of cardiovascular risk factors is termed the metabolic syndrome (MS), which strongly predicts the risk of diabetes and cardiovascular disease (CVD). Adipokines may contribute to the development of obesity and insulin resistance and may be a causal link between MS, diabetes and CVD. Hence, we studied the adipokines - adiponectin and plasminogen activator inhibitor-1 (PAI-1) - in subjects with MS.

Materials and methods: We studied 50 subjects with MS diagnosed by International Diabetes Federation (IDF) criteria and 24 healthy age- and sex-matched controls. Clinical evaluation included anthropometry, body fat analysis by bioimpedance, highly sensitive C-reactive protein, insulin, adiponectin, and PAI-1 measurement.

Results: Subjects with MS had lower adiponectin (4.01 ± 2.24 vs. 8.7 ± 1.77 μg/ml; P < 0.0001) and higher PAI-1 (53.85 ± 16.45 vs. 17.35 ± 4.45 ng/ml; P < 0.0001) levels than controls. Both were related with the number of metabolic abnormalities. Adiponectin was negatively and PAI-1 was positively associated with body mass index, waist hip ratio (WHR), body fat mass, percent body fat, and all the parameters of MS, except HDL where the pattern reversed. WHR and triglycerides were independent predictors of adipokines in multiple regression analysis. Receiver operating characteristic curve analysis showed that adiponectin (6.7 μg/ml) and PAI-1 (25.0 ng/ml) levels predicted the MS with high sensitivity, specificity and accuracy in Indian population.

Conclusions: Subjects with MS have lower adiponectin and higher PAI-1 levels compared to healthy controls. Lifestyle measures have been shown to improve the various components of MS, and hence there is an urgent need for public health measures to prevent the ongoing epidemic of diabetes and CVD.

Keywords: Adiponectin; hsCRP; insulin resistance; metabolic syndrome; plasminogen activator inhibitor-1.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Adiponectin levels according to the number of metabolic abnormalities
Figure 2
Figure 2
Correlation between adiponectin and PAI-1 among all subjects
Figure 3
Figure 3
PAI-1 according to the number of metabolic abnormalities
See this image and copyright information in PMC

References

    1. Misra A, Misra R, Wijesuriya M, Banerjee D. The metabolic syndrome in South Asians: Continuing escalation and possible solutions. Indian J Med Res. 2007;125:345–54. - PubMed
    1. Chen G, Liu C, Yao J, Jiang Q, Chen N, Huang H, et al. Overweight, obesity, and their associations with insulin resistance and -cell function among Chinese: A cross-sectional study in China. Metabolism. 2010;59:1823–32. - PubMed
    1. Scherer PE. Adipose tissue: From lipid storage compartment to endocrine organ. Diabetes. 2006;55:1537–45. - PubMed
    1. Kadowaki T, Yamauchi T. Adiponectin and Adiponectin Receptors. Endocr Rev. 2005;26:439–51. - PubMed
    1. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83. - PubMed